Safety test of inhaled xenon gas in healthy adults
Official title: Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in HealthyHuman Subjects
Funded at General Biophysics, LLC · NIH-11329025 · Data updated 2026-11-12
This will test whether short sessions of inhaled xenon gas are safe and how they affect immune cells in healthy adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | General Biophysics, LLC NIH-funded |
| Lab location | 1 site (Wayland, United States) |
| Project start | May 13, 2025 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $50,000 |
| NIH project number | 3R42AG073059-03S1 |
| Project ID | NIH-11329025 on NIH RePORTER |
Who could benefit from this research
✓Could help
Healthy adults without cognitive impairment who pass the study's medical screening would be eligible to participate.
✕Less likely to help
People with Alzheimer's disease or other dementias, or those with active medical issues (for example pregnancy, lung or heart problems) who fail screening would not be expected to benefit from this early safety trial.
What this research studies
If you join, you would be a healthy volunteer who breathes a controlled xenon gas mixture for short sessions lasting 10, 20, 30, or 45 minutes. Study staff will monitor vital signs and collect blood samples to look for immune changes and any side effects. The team is especially interested in immune signals related to brain microglia and genetic risk factors like APOE because these pathways may matter for Alzheimer's disease. This Phase 1 trial focuses on short-term safety and biological effects in people without dementia.
Why it matters
Potential benefit: If safe and biologically active, xenon inhalation could point to new ways to protect brain cells and modify immune responses relevant to Alzheimer's disease.
How similar studies have gone: Xenon has been used as an anesthetic and shown neuroprotective effects in animal studies, but its immune effects in healthy humans for Alzheimer's-related targets are largely untested.
Where this research is happening
-
General Biophysics, LLC
Wayland, United States Active
Researchers
- Principal investigator: Ilin, Ilya — General Biophysics, LLC
- Study coordinator: Ilin, Ilya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.